Related Experiment Videos
Disagreement between the Roche Cobas Core and Hybritech TANDEM-E PSA assays when measuring free, complexed and total
C R Tillyer1, M Konings, P T Gobin
1Department of Chemical Pathology, Royal Marsden Hospital, London, UK.
Annals of Clinical Biochemistry
|September 1, 1994
Summary
Different prostate specific antigen (PSA) assays show varying reactivity to free and complexed PSA forms. This suggests separate free and complexed PSA assays may be needed for prostate cancer tumor marker development.
Area of Science:
- Clinical Chemistry
- Oncology
- Biomarker Development
Background:
- Prostate specific antigen (PSA) is a key biomarker for prostate cancer.
- Current PSA assays exhibit variability in detecting different PSA forms.
- Understanding assay differences is crucial for accurate prostate cancer diagnosis and monitoring.
Purpose of the Study:
- To compare the performance of two commercial PSA assays: Roche Cobas Core and Hybritech TANDEM-E.
- To investigate the differential reactivity of these assays towards free and complexed serum PSA.
- To assess the implications for PSA as a clinical tumor marker.
Main Methods:
- Comparative analysis of Roche Cobas Core and Hybritech TANDEM-E PSA assays.
- Assessment of assay reactivity using separated free and complexed forms of serum PSA.
- Evaluation of results in patients diagnosed with prostatic carcinoma.
Main Results:
- Significant differences in reactivity were observed between the Roche and Hybritech PSA assays.
- The Roche assay demonstrated higher responsiveness to free PSA.
- The Hybritech assay showed greater responsiveness to complexed PSA and total serum PSA.
Conclusions:
- Standardization of PSA assays may not fully reconcile discrepancies in patient sample results.
- Separate assays for free and complexed PSA may be required for advancing PSA's role as a tumor marker.
- Further research into differential PSA forms is essential for clinical utility in prostate cancer.